Gilead Prices $4 Billion of Senior Unsecured Notes

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 4, 2014-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion in an underwritten, registered public offering, consisting of three tranches:

• $500 million of 2.050% senior notes maturing in April 2019
• $1,750 million of 3.700% senior notes maturing in April 2024
• $1,750 million of 4.800% senior notes maturing in April 2044

The senior notes are rated A- by Standard & Poor's and Baa1 by Moody's. The offering is expected to close March 7, 2014, subject to customary closing conditions.

Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of certain of our indebtedness, debt-related payments, working capital and the repurchase of our outstanding common stock pursuant to our authorized share repurchase program.

Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC, Goldman, Sachs & Co. and Wells Fargo Securities, LLC acted as joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead's effective shelf registration statement on Form S-3 (File No. 194298) copies of which may be obtained from:

An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission's website at http://www.sec.gov/.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the current market demand for these types of securities and the securities of Gilead, Gilead's ability to consummate the offering in the currently anticipated timeframe or at all and the negotiations between Gilead and the underwriters. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks that could impact the offering are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the U.S. Securities and Exchange Commission, and may be updated by the risk factors set forth in any subsequent filing by Gilead with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.Investors:Patrick O’Brien, 650-522-1936Media:Amy Flood, 650-522-5643